• To provide a signed and dated, written informed consent.

• Aged ≥ 18 years old

• Histologically or cytologically confirmed locally advanced or metastatic NSCLC with documented EGFR mutations from a local laboratory

• ECOG performance status 0-1.

• Predicted life expectancy ≥ 12 weeks

• Patient must have measurable disease according to RECIST 1.1.

• Patient who has progressed or intolerant to standard therapy (except treatment naïve patients in Cohort 4 and Cohort 7: with EGFR Exon20ins; and in Cohort 5 with EGFR sensitizing mutation).

• Patients with brain metastasis (BM) can be enrolled under the condition that BM is stable, neurologically asymptomatic and does not require corticosteroid treatment.

• Adequate organ system function.

‣ Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L

⁃ Platelets ≥ 100 x 10\^9/L

⁃ Hemoglobin ≥ 9 g/dL

⁃ Total bilirubin ≤ 1.5 x ULN if no liver metastases or ≤ 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases

⁃ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN if no liver metastases or ≤ 5 x ULN with liver metastases

⁃ Creatinine ≤ 1.5 x ULN, concurrent with calculated or measured creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault method or ≥ 50 mL/min in 24 hours

⁃ International normalized ratio (INR) ≤ 1.5 x ULN and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;

⁃ Serum amylase ≤ 1.5 x ULN and serum lipase ≤ 1.5 x ULN